[1] Webb GJ, Siminovitch KA, Hirschfield GM. The immunogenetics of primary biliary cirrhosis: A comprehensive review. J Autoimmun, 2015, 64: 42-52.
[2] Fenoglio D, Bernuzzi F, Battaglia F, et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev, 2012, 12: 300-304.
[3] Guan SY, Leng RX, Khan MI, et al. Interleukin-35: a potential therapeutic agent for autoimmune diseases. Inflammation, 2017, 40: 303-310.
[4] Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol, 2007, 37: 3021-3029.
[5] Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis, 2007, 27: 161-172.
[6] Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med, 2009, 361: 888-898. |
